TY - JOUR
T1 - Metabolomic analysis of the effects of omeprazole and famotidine on aspirin-induced gastric injury
AU - Takeuchi, Kenichiro
AU - Ohishi, Maki
AU - Endo, Keiko
AU - Suzumura, Kenichi
AU - Naraoka, Hitoshi
AU - Ohata, Takeji
AU - Seki, Jiro
AU - Miyamae, Yoichi
AU - Honma, Masashi
AU - Soga, Tomoyoshi
N1 - Funding Information:
Conflict of interest The authors have no conflict of interest of any kind related to the work presented in this publication. This study was carried out with support from a Grant from the Ministry of Health, Labour and Welfare, Drug Discovery Platform Research (H20-bio-ippan-011).
PY - 2014/10
Y1 - 2014/10
N2 - Gastric mucosal ulceration and gastric hemorrhage are frequently associated with treatment by non-steroid anti-inflammatory drugs (NSAIDs); however, no convenient biomarker-based diagnostic methods for these adverse reactions are currently available, requiring the use of endoscopic evaluation. We recently reported five biomarker candidates in serum which predict gastric injury induced by NSAIDs in rats, but were unable to clarify the mechanism of change in the levels of these biomarker candidates. In this study, we performed capillary electrophoresis-mass spectrometry-based metabolomic profiling in stomach and serum from rats in which gastric ulcer was induced by aspirin and prevented by co-administration of omeprazole and famotidine. Results showed drug-induced decreases in the levels of citrate, cis-aconitate, succinate, 3-hydroxy butanoic acid, and O-acetyl carnitine in all animals administered aspirin. In contrast, aspirin-induced decreases in the level of 4-hydroxyproline were suppressed by co-administration of omeprazole and famotidine. We consider that these changes were due to the prevention of gastric ulcer and decrease in the amount of collagen in stomach tissue by omeprazole and famotidine, without prevention of the NSAID-induced depression of mitochondrial function. In addition, the decreases in 4-hydroxyproline in the stomach was also detectable as changes in the serum. While further study is needed to clarify limitations of indications and extrapolation to humans, this new serum biomarker candidate of gastric injury may be useful in the monitoring of NSAID-induced tissue damage.
AB - Gastric mucosal ulceration and gastric hemorrhage are frequently associated with treatment by non-steroid anti-inflammatory drugs (NSAIDs); however, no convenient biomarker-based diagnostic methods for these adverse reactions are currently available, requiring the use of endoscopic evaluation. We recently reported five biomarker candidates in serum which predict gastric injury induced by NSAIDs in rats, but were unable to clarify the mechanism of change in the levels of these biomarker candidates. In this study, we performed capillary electrophoresis-mass spectrometry-based metabolomic profiling in stomach and serum from rats in which gastric ulcer was induced by aspirin and prevented by co-administration of omeprazole and famotidine. Results showed drug-induced decreases in the levels of citrate, cis-aconitate, succinate, 3-hydroxy butanoic acid, and O-acetyl carnitine in all animals administered aspirin. In contrast, aspirin-induced decreases in the level of 4-hydroxyproline were suppressed by co-administration of omeprazole and famotidine. We consider that these changes were due to the prevention of gastric ulcer and decrease in the amount of collagen in stomach tissue by omeprazole and famotidine, without prevention of the NSAID-induced depression of mitochondrial function. In addition, the decreases in 4-hydroxyproline in the stomach was also detectable as changes in the serum. While further study is needed to clarify limitations of indications and extrapolation to humans, this new serum biomarker candidate of gastric injury may be useful in the monitoring of NSAID-induced tissue damage.
KW - Capillary electrophoresis-mass spectrometry (CE-MS)
KW - Famotidine
KW - Gastric injury
KW - Metabolomics
KW - Non-steroid anti-inflammatory drugs (NSAIDs)
KW - Omeprazole
UR - http://www.scopus.com/inward/record.url?scp=84893165733&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84893165733&partnerID=8YFLogxK
U2 - 10.1007/s11306-014-0627-0
DO - 10.1007/s11306-014-0627-0
M3 - Article
AN - SCOPUS:84893165733
SN - 1573-3882
VL - 10
SP - 995
EP - 1004
JO - Metabolomics
JF - Metabolomics
IS - 5
ER -